Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410135 · ClinicalTrials.gov registry record
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
A clinical trial, sponsored by Southern Illinois University.
- Completed
- Registry status
- 34
- Enrollment target
NCT02410135: Completed study, sponsored by Southern Illinois University.
NCT02410135 is a clinical trial that has completed, run by Southern Illinois University. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02410135 has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
The objective of this exploratory pilot study is to assess whether Mirabegron (Myrbetriq™) will improve the quality of sleep and Lower Urinary Tract Symptoms (LUTS) in men and women presenting with LUTS and disordered sleep.
Interventions
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-12 |
What the finished NCT02410135 record still lists
NCT02410135 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Mirabegron is the first listed.
NCT02410135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02410135 about?
NCT02410135 is a clinical study titled "Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)". The objective of this exploratory pilot study is to assess whether Mirabegron (Myrbetriq™) will improve the quality of sleep and Lower Urinary Tract Symptoms (LUTS) in men and women presenting with LUTS and disordered sleep.
What is the current status of trial NCT02410135?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2015-04. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02410135?
The interventions under investigation include: Mirabegron (DRUG).
Who is sponsoring clinical trial NCT02410135?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia